Synairgen Share Discussion Threads

[davew28] 21/3/2020 21:49

Will there be an adequate supply of inhalers should there be a positive result? Probably not as complex to manufacture as respirators, but does this require a unique or special one?

[allstar4eva] 21/3/2020 21:46

So what are thoughts on likely market cap pre trial completion?

[nobbygnome] 21/3/2020 21:45

Rest assured, if the trial result is positive, it will be used în an enormous number of patients worldwide! Hence the opportunity here....it could be a life changing investment!

[yet another final] 21/3/2020 21:44

Thanks for that, and yes it indicates usage in non-severe infections, which is even better.

[nobbygnome] 21/3/2020 21:43

So no limit on age although non hospitalised patients need to have a comorbidity.

[nobbygnome] 21/3/2020 21:42

What the protocol says about the patient population

Patients admitted to hospital due to the severity of their COVID-19 disease OR non-hospitalised patients from high-risk co-morbidity groups such as the >65-years of age, or those with hypertension, cardiovascular disease, diabetes or a chronic lung condition

[yet another final] 21/3/2020 21:41

Trump is using an American company, Thermofisher... They can produce 5million tests per weekNcyt will have no chance in the usa

[nobbygnome] 21/3/2020 21:40

This is the protocol...

[yet another final] 21/3/2020 21:39

That's the first step... I wrote about the stages of testing and potentialIn the short term (given that time is of the essence) to get a meaningful result in a trial it is best to test in the sickest individuals, as they have most to gain

[lukead] 21/3/2020 21:35

So you reckon that the company thinks it can be beneficial to everyone young and old with severe or moderate conditions
I wonder if you contact the virus once , can you get again and again

[nobbygnome] 21/3/2020 21:31

No the clinical trial protocol says patients can also be treated at home, which is key for increasing the size of the potential market. Not that doctors are going to keep the label in this sort of circumstance anyway......

[lukead] 21/3/2020 21:29

After reading some postings, is it right that the sng drug to be tested is for in particular and primarily for those unfortunate to be hospitalised with severe symptoms or if testings successful might be of benefit to all cases and young and old?
Also just on the other share Nyct, can these test kits be used in other countries apart from UK,such as Italy and USA. I suppose Trump might just want American companies used.

[nobbygnome] 21/3/2020 21:12

No chance of £1 on Monday but 60p looks nailed on....

[davew28] 21/3/2020 21:06

Thanks for that Likya. Certainly sounds highly promising given the previous success in testing patients with COPD and MERS.

[likya123] 21/3/2020 21:00

davew28...here it is in full....
Thinking £1+ Monday.



UK biotech Synairgen (AIM: SNG) saw its share leap more than 52% to 49.00 pence by close of trading on Friday, after it revealed it has received approvals from the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) to conduct a Phase II trial of its lead product SNG001 (inhaled interferon-beta-1a) in coronavirus (COVID-19) patients.

"We have worked intensively with the relevant authorities and collaborators to enable SNG001 to be assessed in COVID-19 patients. SNG001 has been well tolerated in clinical trials in over 200 respiratory patients to date and has accelerated lung function recovery in two Phase II asthma trials in patients with a cold or flu infection,” said Synairgen chief executive Richard Marsden, adding: “A successful outcome from this trial in COVID-19 patients would be a major breakthrough in the fight against this coronavirus pandemic."

SNG001, which has been licensed to AstraZeneca (LSE: AZN under a $230 million deal, will prevent cell damage in a similar fashion to that of multiple sclerosis (MS) patients, according to analytics firm GlobalData.

Synairgen previously tested SNG001 in patients with chronic obstructive pulmonary disease (COPD) with the common cold or influenza. Lacking an effective anti-viral treatment, those with COPD exacerbations account for the second most likely group of patients to be hospitalized in England. This targets a considerable unmet need and although the trial has currently been paused, initial data showed marked changes in COPD symptoms in patients with a confirmed common cold or influenza.

Previously tested in MERS

Clinical trials in asthma have also shown that treatment with inhaled SNG001 reduced lung viral load and lung pathology in an in vivo swine flu driven model of viral pneumonia. At the time of the Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in 2013, Synairgen collaborated with the National Institutes of Health (NIH) in the USA to show that SNG001 could protect against MERS-CoV infection of lung cells in vitro.

Angad Lotay, infectious diseases analyst at GlobalData, comments: “The human body produces its own interferon-beta (INF-beta), to help reduce inflammation caused by a natural immune response. For many years it has been used as a compound in patients with MS and is administered via subcutaneous injection. There is evidence that deficiency in IFN-beta production by the lung could explain the enhanced susceptibility of ‘at-risk’ patient groups in developing severe lung disease during viral infections. 

“Furthermore, viruses, such as severe acute respiratory syndrome (SARS-CoV-2 and MERS-CoV), have evolved mechanisms which suppress endogenous IFN-beta production, thereby helping the virus evade the innate immune response. Research conducted in Hong Kong has revealed that patients who had recovered from the coronavirus had sustained lung damage, therefore it is possible that patients may not fully recover their lung function following the infection. Synairgen’s SNG001, a formulation of IFN-beta-1a for direct delivery to the lungs via nebulization will therefore prevent cell damage.” 

[davew28] 21/3/2020 20:44

Anyone have access to Pharma Letter?

Headline:

Synairgen’s SNG001 will prevent cell damage in fight against coronavirus pandemic

[bmnsa] 21/3/2020 17:55

Coronavirus: New treatment for critically ill patients to begin trials as soon as next week
The inhaled drug can already help asthma and chronic obstructive pulmonary disease patients with other lung infections.


The experimental drug, code named SNG001, will initially be given to patients at Southampton General Hospital as part of the first trial of its kind.

Doctors have high hopes that it could also help stop the coronavirus in its tracks.

The inhaled treatment has already been shown to improve the recovery of asthma and COPD (chronic obstructive pulmonary disease) patients who have other lung infections . . . . . .


hxxps://news.sky.com/story/coronavirus-new-treatment-for-critically-ill-patients-to-begin-as-soon-as-next-week-11959914

[bmnsa] 21/3/2020 17:43

thwarnts
If only.
I'm closing other positions and going all out with SNG.

[talk2dubya] 21/3/2020 17:30

See Trump was talking about FDA fast tracking therapeutics to deal with the situation now.

[thwarnts] 21/3/2020 15:48

Surely the MM's are going to come looking for those stop losses in the next 2 weeks, any major drop IMV is a massive BUY signal. GL to holders

[talk2dubya] 21/3/2020 15:31

Apparently people are overdosing in Nigeria from chloroquine at the moment (available freely because of malaria).

[yet another final] 21/3/2020 15:26

Interesting news re treatment.....Hydroxychloroquine(HC) reduced viral load in infected patients, and this effect was greater in those where Azithromicin was added

Quite curious, because these were never designed to treat viruses in general.

Perhaps the next step in the evolution of therapy is the combination of HC/Azith and Inhaled SNG001